#BCVA
LightNews LightNews
secwatch.bsky.social
🚨 JUST IN: $EYPT
EyePoint's LUCIA Phase 3 DURAVYU trial misses primary BCVA non-inferiority endpoint in wet AMD

#SEC #stocks #investing #EYPT
🔗 secwatch.observer
EyePoint's LUCIA Phase 3 DURAVYU trial misses primary BCVA non-inferiority endpoint in wet AMD
October 19, 2026 at 11:22 AM
biostock.bsky.social
🔴 #$EYPT — Clinical Readout
LUCIA Phase 3 Topline - Primary Endpoint Not Met (Wet AMD)
LUCIA (n=475) did not achieve non-inferiority in BCVA vs on-label aflibercept (+2.5 vs +6.1 letters, difference -3.7, CI outside the 4.5 letter margin). Secondary endpoints m…

https://biostock.app/symbols/EYPT
October 19, 2026 at 11:33 AM
niallgrimc.bsky.social
Day 2 of BCVA conference.Great freebie, but rubbish for brushing your teeth
October 16, 2026 at 8:30 AM
nestormarts.eurosky.social
Uno piensa que lo estás haciendo mal, el otro que no les bçva a quedar nada para ellos.
October 16, 2026 at 5:16 PM
srucvets.bsky.social
Just two days until BCVA Congress!
The team from SRUC Veterinary Services is looking forward to catching up with customers, colleagues and friends.
We can help with:
✅ CPD
✅ C-QAS
✅ HerdPlan
✅ Health Schemes
✅ Diagnostic testing services

📍 Stand 6

#BCVA #CattleVet #FarmVet #SRUC #VetCPD
October 13, 2026 at 9:07 AM
srucvets.bsky.social
🐄 🐂 How "closed" is a closed herd when a new bull is bought?

Join Helen Carty & Martin Tomlinson at BCVA Congress 2026 to learn how to interpret CHeCS pen cards, EBVs and disease risk information to support better bull-buying decisions.

📅 15 Oct | 16:00-17:30 #BCVACongress #CattleVet
October 7, 2026 at 1:56 PM
srucvets.bsky.social
🐄 Just 2 weeks until #BCVACongress2026!

The SRUC Veterinary Services team will be on Stand 6 talking diagnostic testing, C-QAS, HerdPlan, vet CPD, health schemes and more.

If you're attending, be sure to pop by and say hello to Alison and Roz! 👋

#BCVA #FarmVet #CattleHealth
October 1, 2026 at 10:00 AM
cjo-jco.bsky.social
This photo essay illustrates tumour regression in a patient with sporadic retinal capillary hemangioma (RCH) after belzutifan monotherapy and laser photocoagulation.

bit.ly/cjo_retinal-...

#Ophthalmology #OcularOncology
Sporadic retinal capillary hemangioma regresses with belzutifan
A 59-year-old woman presented with right-eye photopsia and best-corrected visual acuity (BCVA) of 20/20. She was diagnosed with a sporadic retinal capillary hemangioma (RCH), given normal VHL-germline...
bit.ly
September 14, 2026 at 11:04 AM
biostock.bsky.social
🔴 #$EYPT — Clinical Readout
LUGANO Expanded Topline Results - Primary Endpoint Not Met in Full Analysis (Wet AMD)
EyePoint posted an updated investor presentation with expanded LUGANO Phase 3 results. DURAVYU did not achieve statistical non-inferiority in BCVA …

https://biostock.app/symbols/EYPT
September 10, 2026 at 11:56 AM
research.migraine.kr
Both groups were evaluated ophthalmologically and imaged by optical coherence tomography angiography (OCTA) to evaluate both retinal thickness and vasculature.

RESULTS: Both groups were well matched regarding age, sex, best corrected visual acuity (BCVA), axial length, (🧵 3/6)
September 10, 2026 at 9:51 AM
paper.migraine.kr
두 그룹 모두 안과적 검사를 받았으며, 망막 두께와 혈관 구조를 평가하기 위해 광학 일관성 단층 촬영 혈관조영술(OCTA)을 통해 영상을 촬영했다.

결과: 두 그룹은 연령, 성별, 최선 교정 시력(BCVA), 축거리, 구면 등가(SER) 및 안압(IOP) 측면에서 잘 매칭되었으며, 유의한 차이는 없었습니다. 편두통군은 대조군에 비해 모든 혈관 매개변수에서 유의미한 감소를 보였으며, (🧵 2/3)
September 10, 2026 at 9:43 AM
ophthalmology.bsky.social
Ophthopedia Update: 358 Associations of area deprivation and social vulnerability indices with pediatric vision screening outcomes in the UCI EyeMobile for Children Program: Area Deprivation Index (ADI) and Social Vulnerability Index (SVI) are nationally… #Ophthalmology #Eye #Ophthotwitter
358 Associations of area deprivation and social vulnerability indices with pediatric vision screening outcomes in the UCI EyeMobile for Children Program
Area Deprivation Index (ADI) and Social Vulnerability Index (SVI) are nationally validated neighborhood measures associated with pediatric health outcomes. Evidence in pediatric ophthalmology is limited. To our knowledge, this is the first study to examine ADI/SVI with school-based vision screening outcomes, refractive error (RE), amblyopia, and best-corrected visual acuity (BCVA).
dlvr.it
August 29, 2026 at 1:12 AM
sajilicious.bsky.social
youtube.com/watch?v=BCVA...

There are no global or national laws around geo-engineering, so anyone could try to play god and try to modify the weather e.g. like blocking the sun like in The Matrix #climatechange

Crossposted with @openvibe.social
A Brief History of Climate Folly with Tim Flannery | Webinar
youtube.com
August 18, 2026 at 12:15 AM
chop-pubs.bsky.social
Binh Cao, Brad Kline, Brandon Kao, Yinxi Yu, Gui-Shuang Ying, Julius T Oatts, Steven J Gedde, Iqbal Ike K Ahmed, and Ying Han
Three-Year Treatment Outcomes of Ahmed Glaucoma Valve Implantation with Adjunctive Intraoperative and Postoperative Mitomycin C
CONCLUSIONS: AGV implantation combined with intraoperative and postoperative MMC resulted in a significant reduction in IOP and number of glaucoma medications with a low rate of surgical complications and stable BCVA during 3 years of follow-up.
linkinghub.elsevier.com
August 18, 2026 at 4:00 AM
stocktitan.net
#EYPT EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

https://www.stocktitan.net/news/EYPT/eye-point-announces-topline-data-from-lugano-the-first-of-two-dpho60a976em.html
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
EyePoint (Nasdaq:EYPT) reported topline results from LUGANO, the first pivotal Phase 3 trial of DURAVYU™ 2.7mg in wet AMD versus on‑label 2 mg aflibercept. The primary endpoint (BCVA change) was not achieved in the full dataset, affected by a 4% asymmetric cohort (9/211 DURAVYU patients) with ≥15‑letter vision loss unrelated to wet AMD; no such cases occurred in the aflibercept arm. An ad hoc analysis excluding this cohort showed non‑inferiority for DURAVYU (nominal p=0.0096).Key secondary endpoints favored DURAVYU, including a 42% reduction in treatment burden (two fewer injections on average; p<0.0001), high supplement‑free rates (76% to Week 32; 54% to Week 56; 79% with 0–1 supplement to Week 56), non‑inferior BCVA in supplement‑free patients (p=0.0035), strong anatomic control with a 4‑micron CST difference at Week 56 (3 microns in supplement‑free eyes), and a favorable safety profile with repeat dosing. EyePoint expects topline data from the second pivotal wet AMD trial, LUCIA, in Q4 2026 and is planning a potential FDA NDA submission for DURAVYU in 1H 2027, pending those results. Phase 3 DME trials COMO and CAPRI have fully enrolled, with topline data anticipated in Q4 2027.
www.stocktitan.net
August 17, 2026 at 11:00 AM
cachorrotegui.bsky.social
@j en Egipto XX. HH Gv Vcv mmoo kjkztjzxxxxx a BCva CC
May 25, 2025 at 10:29 AM
digitaldesert.bsky.social
This is a weird development.
Trump’s money losing media company to merge with a fusion energy development company with no revenues.

f24.my/Bcva
Trump Media announces merger with fusion power company
Trump Media & Technology Group, the struggling company that owns the US president's Truth Social platform, announced Thursday a $6 billion merger with fusion power company TAE Technologies, in an unex...
f24.my
December 18, 2025 at 3:38 PM
ophthoscope.bsky.social
Novel classification for microspherophakia and its related surgical implications: a retrospective cohort study

Background A novel classification for microspherophakia (MSP) was developed using a nomogram model to stratify patients and evaluate surgical outcomes. Methods The study involved 99 eyes
Novel classification for microspherophakia and its related surgical implications: a retrospective cohort study
Background A novel classification for microspherophakia (MSP) was developed using a nomogram model to stratify patients and evaluate surgical outcomes. Methods The study involved 99 eyes from 64 MSP patients, divided into training (64 eyes) and validation (35 eyes) cohorts. Primary outcome included the best corrected distance visual acuity (BCVA) at the 1-year follow-up, and the secondary outcome was intraocular pressure (IOP) control. MSP patients achieving a BCVA of ≤0.2 logarithm of the minimal angle of resolution with successful IOP control were categorised into the favourable outcomes group, while those not meeting these criteria were placed in the unfavourable outcomes group. A nomogram model was constructed to predict unfavourable outcomes by identifying associated risk factors. Results In the training cohort, 39.06% (25/64) achieved favourable outcomes, while 60.94% (39/64) had unfavourable outcomes. Decreased anterior chamber depth (ACD) and the presence of glaucoma were identified as risk factors for predicting unfavourable outcomes. The concordance index for the training and validation cohorts was 0.828 and 0.768, respectively. A nomogram-derived cut-off value of 56 points stratified patients into low-risk (≤56 points) and high-risk (>56 points) groups. Postoperative BCVA was significantly better in the low-risk group at 6-month and 1-year follow-ups. Conclusion MSP patients in the low-risk group achieved satisfactory outcomes. For high-risk patients with shallowing ACD, early surgical intervention is recommended to prevent secondary glaucoma. Close monitoring of IOP and glaucoma progression is crucial for patients with secondary glaucoma. This classification offers valuable insights for outcome stratification and guidance in clinical decision-making for MSP management. However, the limitations of this study include its small sample size, which may impact generalisability, and future studies with larger cohorts are needed to validate and refine the nomogram.
bmjophth.bmj.com
May 2, 2025 at 11:02 AM
ophthoscope.bsky.social
Natural history of progressive vision loss in Bietti crystalline dystrophy: a model-based meta-analysis

Purpose Bietti crystalline corneoretinal dystrophy (BCD) is an autosomal recessive progressive retinal degenerative disease due to mutations in the CYP4V2 gene. Best-corrected visual acuity (BC
Natural history of progressive vision loss in Bietti crystalline dystrophy: a model-based meta-analysis
Purpose Bietti crystalline corneoretinal dystrophy (BCD) is an autosomal recessive progressive retinal degenerative disease due to mutations in the CYP4V2 gene. Best-corrected visual acuity (BCVA) is a common primary endpoint in clinical trials for retinal diseases, but the natural history of BCVA loss remains unclear because of the heterogeneity of manifestations in BCD patients. Methods Based on the individual data of untreated BCD patients, a disease progression model was established using the change in BCVA from baseline as an index, and covariates including age of onset, age, duration of disease, baseline BCVA, gender, race (East Asian/non-East Asian), genotype, and family history. Then, based on the final model, the natural disease progression characteristics of BCD were simulated. Result A total of 14 studies met the inclusion criteria, with a total sample size of 117 cases, including 6 studies (N=80) with East Asian populations and 9 studies (N=37) with non-East Asian populations. The change of BCVA from baseline increased linearly with time, and the disease progression model of BCD was successfully established. BCVA increased by 0.06 logarithm of the minimum angle of resolution (LogMAR) per year in BCD patients. BCVA increased by 0.09 LogMAR per year in patients with BCVA≥0.5LogMAR and disease duration more than 10 years. Conclusions For the first time, we successfully established a BCD disease progression model based on the change in BCVA from baseline. The mean visual acuity loss increased linearly with the progression of the disease. A sharper loss of BCVA may be expected in patients with BCVA≥0.5LogMAR and disease duration ≥10 years.
bmjophth.bmj.com
April 12, 2025 at 9:01 PM
leanhealth.bsky.social
Covid geht ins Auge - kleine prospektive Studie bei 56 milden Covid Genesenen - 1 Jahr nach Erkrankung

Sig. Veränderungen in ALLEN Werten: CD, CV, %hex, AVG,CCT, K1,K2,Kmean, Kmax, CCT, TA,CAf &b, BCVA

Auffallend waren die Abnahme der Endothelzellzahl

t1p.de/zl3u2
COVID-19 Related Changes in Corneal Curvature and Endothelium after Mild Infection
To investigate subclinical corneal changes using corneal topography in the evaluation of corneal curvature and specular microscopy in the evaluation o…
t1p.de
November 26, 2023 at 6:49 PM
babygoldie.bsky.social
[3/4] The results showed that the average change in best-corrected visual acuity (BCVA) from baseline in the HLX04-O group at weeks 36 and 48 was non-inferior to the ranibizumab group, and the safety profile was
June 16, 2026 at 10:02 AM
babygoldie.bsky.social
[3/4] The results showed that the average change in best-corrected visual acuity (BCVA) from baseline in the HLX04-O group at weeks 36 and 48 was non-inferior to the ranibizumab group, and the safety profile was
June 16, 2026 at 10:00 AM
juliebwriter.bsky.social
British Journal of Ophthalmology (preliminary study):
“[88] Participants received either five consecutive days of theta-burst TMS or conventional conservative care. Primary outcomes were changes in best-corrected visual acuity (BCVA) and visual field from baseline to 4-week follow-up”
#RP #MMD
ophthalmology.bsky.social Ophthopedia @ophthalmology.bsky.social · Jul 31
Ophthopedia Update: Transcranial magnetic stimulation as a novel therapeutic approach for severe retinal degenerative diseases: a pilot study: Background

Retinal degenerative diseases, including myopic macular degeneration (MMD) and retinitis pigmentosa (RP),… #Ophthalmology #Ophthotwitter #BJO
Transcranial magnetic stimulation as a novel therapeutic approach for severe retinal degenerative diseases: a pilot study
Background Retinal degenerative diseases, including myopic macular degeneration (MMD) and retinitis pigmentosa (RP), lead to irreversible vision impairment, with limited treatment options. Transcranial magnetic stimulation (TMS), a non-invasive brain stimulation technique for rehabilitation, may hold potential for vision restoration. The pilot study explored whether TMS is associated with short-term functional visual improvements in patients with severe retinal degenerative diseases.Methods This prospective, non-randomised, parallel-arm pilot study enrolled 98 patients with bilateral severe MMD or RP. Participants received either five consecutive days of theta-burst TMS or conventional conservative care. Primary outcomes were changes in best-corrected visual acuity (BCVA) and visual field from baseline to 4-week follow-up. Contrast sensitivity, macular sensitivity, fixation stability, Visual Function Index-14 (VF-14) and Visual Functioning Questionnaire-25 (VFQ-25) questionnaires were also evaluated. A subset of participants underwent resting-state functional magnetic resonance imaging (fMRI) to explore cortical functional changes.Results The study analysed 174 eyes from 88 patients (mean age: 60.3±9.1 years; 52% female). Compared with controls, the TMS group showed greater improvements in BCVA (MMD: 0.22±0.28 logarithm of the minimum angle of resolution (logMAR); RP: 0.24±0.21 logMAR) and VF mean defect (MMD: 1.96±2.09 dB; RP: 1.08±1.28 dB). Contrast sensitivity, macular sensitivity and fixation stability also showed short-term gains. Patient-reported outcomes improved in several functional domains. fMRI demonstrated increased activity and functional connectivity in visual-related cortical regions following TMS.Conclusions In this exploratory pilot study, TMS treatment was associated with short-term functional visual improvements and cortical modulation in individuals with severe retinal degenerative diseases. These findings are hypothesis-generating and warrant validation through larger, randomised, masked clinical trials with longer follow-up.
dlvr.it
August 1, 2026 at 6:06 PM